Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.41 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697044 | 0.88 | LRRK2 (0.47) | F10LRRK2EPHB3MAPTMEN1 | |
| SCHEMBL46914 | 0.85 | LRRK2 (0.43) | F10LRRK2 | |
| SCHEMBL46905 | 0.81 | LRRK2 (0.46) | F10LRRK2EPHB3SMN1; SMN2NPC1 | |
| SCHEMBL40295 | 0.80 | LRRK2 (0.49) | F10LRRK2SMN1; SMN2NPC1TP53 | |
| SCHEMBL46897 | 0.80 | LRRK2 (0.49) | F10LRRK2SMN1; SMN2NPC1TP53 | |
| SCHEMBL266507 | 0.79 | HTR6 (0.49) | F10SERPINE1SMN1; SMN2NPC1TP53 | |
| SCHEMBL46588 | 0.79 | F10 (0.41) | F10LRRK2SMN1; SMN2MAPT | |
| SCHEMBL46908 | 0.78 | F10 (0.42) | F10LRRK2 | |
| SCHEMBL267854 | 0.77 | NPC1 (0.48) | SERPINE1SMN1; SMN2NPC1TP53MAPT | |
| SCHEMBL10149225 | 0.77 | IP6K1 (0.53) | F10LRRK2EPHB3SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-2590965-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-9289429-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289429-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150157637-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150157637-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-11 | — | — | US | disclosed |
| US-8809339-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809339-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006474-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150157637-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A1 | F10 1711/4885LRRK2 4388/4885SERPINE1 2242/4885 |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A3 | F10 1866/4885LRRK2 4304/4885SERPINE1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.